Hogar » Últimas publicaciones y patentes sobre biotecnología y CRISPR

Últimas publicaciones y patentes sobre biotecnología y CRISPR

CRISPR

Esta es nuestra última selección de publicaciones y patentes mundiales en inglés sobre Biotecnología y CRISPR, entre muchas revistas científicas en línea, clasificadas y centradas en CRISPR, edición de genes, gRNA, secuencia PAM, escisión de ADN, proteína Cas9, edición del genoma, inserción de genes y knockout de genes.

Publicación: no hay noticias recientes sobre este tema en particular. Pruebe a realizar una búsqueda manual exhaustiva en la base de datos de publicaciones a la que se hace referencia más arriba.

Rationally-designed synthetic peptide shuttle agents for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a

Patent published on the 2025-05-21 in EP under Ref EP4556567 by FELDAN BIO INC [CA] (Del'guidice Thomas [ca], Lepetit-stoffaes Jean-pascal [ca], Guay David [ca])

Abstract: The present description relates to methods for delivering polypeptide cargos from an extracellular space to the cytosol and/or nucleus of a target eukaryotic cell. The methods involve contacting the cell with the polypeptide cargo in the presence of a peptide shuttle agent at a concentration sufficient to increase the polypeptide cargo's transduction efficiency. Also described here are parameters that may be used in the rational design of such synthetic peptide shuttle agents, peptide shuttle ag[...]


Our summary: Methods for delivering polypeptide cargos using synthetic peptide shuttle agents to increase transduction efficiency in target eukaryotic cells. Parameters for rational design, shuttle agents satisfying design parameters, and compositions for delivering various polypeptide cargos are also discussed. Applications and targets for genome-editing NK cells for improved immunotherapy are included.

synthetic peptide, shuttle agents, polypeptide cargos, transduction efficiency

Patent

Genome editing of plant jaz genes for pathogen resistance and improved fiber quality and yield

Patent published on the 2025-03-06 in WO under Ref WO2025050099 by TEXAS TECH UNIV SYSTEM [US] (Rock Chris [us], Sukumaran Sunitha [us])

Abstract: Embodiments of the present disclosure pertain to a plant or seed that includes one or more altered JASMONATE-ZIM DOMAIN repressor (JAZ) genes. Additional embodiments of the present disclosure pertain to methods of altering one or more JAZ genes of a plant or seed by introducing one or more alterations to the one or more JAZ genes of the plant or seed. The altered plants and seeds of the present disclosure may exhibit one or more altered properties, such as jasmonic acid (JA) insensitivity, enhan[...]


Our summary: Genome editing of plant JAZ genes for pathogen resistance and improved fiber quality and yield. Altered plants and seeds with enhanced resistance to pathogens and insects, and improved fiber yield and quality.

Genome editing, Plant, JAZ genes, Pathogen resistance

Patent

Tabla de contenido
    Ajoutez un en-tête pour commencer à générer la table des matières

    ¿DISEÑO o RETO DE PROYECTO?
    Ingeniero Mecánico, Gerente de Proyectos o de I+D
    Desarrollo eficaz de productos

    Disponible para un nuevo desafío a corto plazo en Francia y Suiza.
    Contáctame en LinkedIn
    Productos de plástico y metal, Diseño a coste, Ergonomía, Volumen medio a alto, Industrias reguladas, CE y FDA, CAD, Solidworks, Lean Sigma Black Belt, ISO 13485 Clase II y III médica

    Buscamos un nuevo patrocinador

     

    ¿Su empresa o institución se dedica a la técnica, la ciencia o la investigación?
    > Envíanos un mensaje <

    Recibe todos los artículos nuevos
    Gratuito, sin spam, correo electrónico no distribuido ni revendido.

    o puedes obtener tu membresía completa -gratis- para acceder a todo el contenido restringido >aquí<

    Temas tratados: Biotechnology, CRISPR, gene editing, gRNA, PAM sequence, DNA cleavage, Cas9 protein, genome editing, gene insertion, gene knockout, neural excitatory/inhibitory imbalance, therapeutic challenges, ISO 21571, ISO 9001, ISO 13485, ISO/IEC 17025, and ISO 15189..

    1. Lexi

      Interesting read, but dont you think the ethical implications of CRISPR should be addressed more thoroughly in these publications?

    2. Charli Case

      Interesting read, but shouldnt there be more public debate on ethical implications before CRISPR becomes commonplace? Just food for thought.

    3. Valery Hoover

      Interesting read! But do we have enough ethical guidelines in place to regulate these CRISPR advancements? Just food for thought.

    Los comentarios están cerrados.

    Publicaciones relacionadas

    Scroll al inicio

    También te puede interesar